Wednesday, November 18, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 51

FDA moves to yank liquid statin FloLipid off US shelves

The FDA wants to pull its approval of FloLipid, a liquid simvastatin sold by Oklahoma-based Salerno Pharmaceuticals, after the company repeatedly skipped required annual reports and ignored the agency's requests. Without approval, the 20-mg and 40-mg doses could no longer be legally sold across the US.

By the Paparazzi desk November 18, 2026 · 12:56 PM · cardiovascularbusiness.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: cardiovascularbusiness.com.
  • The source published it on Nov 18, 2026 at 12:56 PM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

The FDA has proposed withdrawing its approval of FloLipid, the liquid simvastatin made by Oklahoma-based Salerno Pharmaceuticals, after the manufacturer failed on multiple occasions to file required reports — and failed to answer the agency's requests for them. The move, signed by Michael Davis, MD, PhD, director of the FDA's Center for Drug Evaluation and Research, would effectively take the drug off shelves nationwide.

The proposal covers the 20-mg and 40-mg doses of the liquid statin, which Salerno markets as the first cholesterol medication in liquid form for U.S. patients. It was designed for people who struggle to swallow pills and does not need refrigeration. The FDA first approved the company's simvastatin formulation in 2016.

Sponsored

Companies that win approval of a new drug application must file annual reports to keep it. According to the Federal Registrar, Salerno has until Dec. 18 to request a hearing, then until Jan. 19, 2027, to hand over all relevant data and written comments.

If the company misses the hearing deadline, the FDA says that counts as a waiver of any arguments about the drug's legal status. The proposal states the agency would then withdraw approval, and the products could no longer be lawfully introduced or delivered into interstate commerce. Any new drug product shipped without an approved NDA, the FDA adds, is subject to regulatory action at any time.

TopicsFDA · Salerno Pharmaceuticals · FloLipid · simvastatin · Michael Davis · Center for Drug Evaluation and Research

Share

Source: cardiovascularbusiness.com

Written by AI from verified reporting.

More stories

  • Health & science 22:51 UTC · 59 minutes ago · cnbc.com · Caught by @bayu.lestari45 · 0 views
    FDA's Case Against Cheap-Drug Sellers Rests on a Rival CEO Turned Informant
  • Health & science 22:46 UTC · 1 hour ago · x.com · 0 views
    Adults Ask About Another Measles Shot as US, Mexico and Bolivia Lose Elimination Status
  • Health & science 19:31 UTC · 4 hours ago · finance.yahoo.com · 1 view
    Ionis' Tryngolza becomes EU's first RNA therapy for severe high triglycerides
  • Health & science 18:16 UTC · 6 hours ago · theguardian.com · 0 views
    E coli toxin colibactin flagged to MPs as prime suspect in under-50 bowel cancer rise
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.